Encouraging interim results have supported Roche’s decision to move trontinemab into a pivotal Phase III programme.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback